

**ASX RELEASE**

**15 February 2022**

**AMPLIA ABSTRACT ACCEPTED FOR PRESENTATION AT MAJOR CANCER CONFERENCE**

- *Abstract presenting data from the Phase 1 clinical trial of AMP945 has been accepted for presentation and publication at the American Association for Cancer Research meeting in April 2022.*

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new approaches for the treatment of cancer and fibrosis, is pleased to announce that a clinical trial abstract describing the results of its Phase 1 clinical trial of AMP945 has been accepted for presentation at the American Association for Cancer Research (AACR) Meeting that will be held in New Orleans from April 8<sup>th</sup> to 13<sup>th</sup> 2022.

The abstract entitled “A Phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers” describes the results from Amplia’s Phase 1 clinical trial of AMP945 in healthy volunteers which completed in 2021. This trial showed that AMP945 was safe and well tolerated, could be administered orally once a day, and was able to inhibit its intended target, focal adhesion kinase (FAK), in tissue samples taken from participants in the study<sup>1</sup>. On the back of the successful data from this trial, Amplia intends to initiate a Phase 2 clinical trial in first line pancreatic cancer patients in early Q2 2022. This abstract will be presented at the AACR Meeting in early April 2022 and also published online in the *Proceedings of the AACR*.

“The AACR is one of the most recognised international forums for cancer research and we are delighted that the results of our Phase 1 trial have been selected for presentation at this prestigious meeting,” said Dr. John Lambert, CEO of Amplia. “We believe the approach we are taking using AMP945 to potentially improve the current standard of care treatment for pancreatic cancer is well supported by our Phase 1 clinical trial data and the results from a number of nonclinical studies we have conducted.”

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

**For Further Information**

Dr. John Lambert  
CEO and Managing Director  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

---

<sup>1</sup> Summary Results from Successful Phase 1 Clinical Trial of AMP945 – 18 November 2021